Express News | Vivos Therapeutics Shares Are Trading Higher After Ascendiant Capital Maintained a Buy Rating on the Stock and Raised Its Price Target From $6.4 to $6.6
Express News | Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $6.6
Vivos Therapeutics Analyst Ratings
Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript Summary
Vivos Therapeutics GAAP EPS of -$0.60, Revenue of $4.1M
Vivos Therapeutics | 10-Q: Q2 2024 Earnings Report
Earnings Flash (VVOS) VIVOS THERAPEUTICS Posts Q2 Revenue $4.1M
Express News | Vivos Therapeutics Q2 Operating Expenses USD 4.587 Million
Express News | Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
Express News | Vivos Therapeutics Q2 Operating Income USD -1.936 Million
Express News | Vivos Therapeutics Q2 Gross Profit USD 2.651 Million
Express News | Vivos Therapeutics Q2 Basic EPS USD -0.6
Vivos Therapeutics Files Registration Statement for Secondary Sale of Securities
Vivos Therapeutics | 10-K/A: Annual report (Amendment)
Vivos Therapeutics Receives Notice Of Allowance For US Patent Application 18/215,930 Titled "Vibrational Oral Appliance With Mandibular Advancements For Temporary Relief From Sleep Disordered Breathing, Sleep Apnea, And/Or Snoring"
Vivos Gains as Pilot Program Validates New Market Model
Express News | Vivos Therapeutics Reveals Positive Results From A 7-month, Multi-site Marketing Pilot, Testing Core Assumptions Behind Company's New Affiliation And Medical Sleep Specialist Marketing And Distribution Model
Express News | Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of Its New Provider-Based Marketing and Distribution Model
Vivos Therapeutics Reports Positive Results From Pilot of Provider-based Model | NASDAQ:VVOS
Express News | Vivos Therapeutics Disclosed The Closing Of $7.5M At-The-Market Private Equity-Backed Investment And Launch Of Strategic Marketing And Distribution Alliance
No Data